Status:
UNKNOWN
Identification of Clinically Occult Glioma Cells and Characterization of Glioma Behavior Through Machine Learning Analysis of Advanced Imaging Technology
Lead Sponsor:
AHS Cancer Control Alberta
Conditions:
Glioma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Gliomas are one of the most challenging tumors to treat, because areas of the apparently normal brain contain microscopic deposits of glioma cells; indeed, these occult cells are known to infiltrate s...
Detailed Description
Gliomas are the most common primary brain tumors in adults; most are high-grade and have a high level of mortality. The standard treatment is to kill or remove the cancer cells. Of course, this can on...
Eligibility Criteria
Inclusion
- must have histologically proven glioma
- the patient or legally authorized representative must fully understand all elements of informed consent, and sign the consent form
Exclusion
- psychiatric conditions precluding informed consent
- medical or psychiatric condition precluding MRI or PET studies (e.g. pacemaker, aneurysm clips, neurostimulator, cochlear implant, severe claustrophobia/anxiety, pregnancy)
Key Trial Info
Start Date :
June 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2017
Estimated Enrollment :
113 Patients enrolled
Trial Details
Trial ID
NCT00330109
Start Date
June 1 2006
End Date
December 1 2017
Last Update
January 16 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cross Cancer Institute
Edmonton, Alberta, Canada, T6G 1Z2